Basic Information
ID: ALA5257136
Journal: ACS Med Chem Lett
Title: PROTAC Targeted Degradation of IRAK-4 as Potential Treatment in Cancer.
Authors: Kargbo RB.
Abstract: Toll-like receptors and interleukin-1 receptor directly interact with intracellular interleukin receptor associated kinase (IRAK) family members to initiate innate immune and inflammatory responses following activation by pathogens. The IRAK family members are involved in linking the innate immune response to the pathogenesis of various diseases, including cancers, non-infectious immune disorders, and metabolic disorders. The Patent Highlight showcases exemplary PROTAC compounds that exhibit a broad range of pharmacological activities associated with degradation of protein targets for the treatment of cancer.
CiteXplore: 37197458
DOI: 10.1021/acsmedchemlett.3c00112
Patent ID: ┄
Associated Items: Associated Bioactivities Associated Assays Associated Compounds Associated Targets